NantHealth (NASDAQ:NH) Earns Hold Rating from Analysts at started coverage on shares of NantHealth (NASDAQ:NHGet Rating) in a research report issued to clients and investors on Wednesday. The brokerage set a “hold” rating on the stock.

Several other brokerages have also commented on NH. The Goldman Sachs Group raised NantHealth from a “neutral” rating to a “buy” rating in a research report on Friday, January 7th. Zacks Investment Research upgraded NantHealth from a “sell” rating to a “hold” rating in a research note on Tuesday, March 1st.

NH opened at $0.71 on Wednesday. The firm has a market cap of $82.02 million, a P/E ratio of -1.42 and a beta of 1.75. The firm has a 50-day moving average of $0.79 and a 200 day moving average of $1.06. NantHealth has a fifty-two week low of $0.68 and a fifty-two week high of $2.87.

NantHealth (NASDAQ:NHGet Rating) last released its quarterly earnings data on Thursday, February 24th. The company reported ($0.11) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.01). The business had revenue of $16.03 million for the quarter, compared to analyst estimates of $16.00 million. During the same quarter in the previous year, the business posted ($0.07) earnings per share. Equities analysts predict that NantHealth will post -0.39 EPS for the current year.

Several institutional investors have recently made changes to their positions in the company. Barclays PLC increased its holdings in NantHealth by 196.9% during the 4th quarter. Barclays PLC now owns 32,661 shares of the company’s stock worth $34,000 after purchasing an additional 21,662 shares during the period. Millennium Management LLC acquired a new stake in NantHealth during the 2nd quarter worth approximately $44,000. Goldman Sachs Group Inc. acquired a new stake in NantHealth during the 2nd quarter worth approximately $61,000. Wells Fargo & Company MN lifted its position in NantHealth by 676.0% during the 4th quarter. Wells Fargo & Company MN now owns 160,307 shares of the company’s stock worth $169,000 after acquiring an additional 139,650 shares during the period. Finally, Allspring Global Investments Holdings LLC acquired a new stake in shares of NantHealth in the 4th quarter valued at approximately $181,000. 5.38% of the stock is currently owned by institutional investors and hedge funds.

About NantHealth (Get Rating)

NantHealth, Inc, together with its subsidiaries, operates as a healthcare IT company in the United States, Canada, and the United Kingdom. It offers Eviti, a software-as-a-service (SaaS) based clinical decision support solution that centralizes clinical content and treatment cost data from Medicare reimbursements and treatment toxicity data; Eviti Connect, which utilizes the platform to offer pre-authorization automation that helps payers and providers navigate the complexities of cancer care; and Eviti Advisor product that allows physicians to access the Eviti platform's comprehensive library of evidence-based treatment standards and protocols to inform treatment decisions.

Read More

Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with's FREE daily email newsletter.